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Background on MEND
Role players in the global effort to combat the three main “diseases of  
poverty”(malaria, TB, and HIV/AIDS)
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MEND was founded to fill the gap in global effort to combat the three 
main “diseases of  poverty”
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• Only 13 of  the 1,223 drugs 
developed since 1975 have been for 
neglected diseases*
• Since 1990, thousands of  articles on 
“breakthrough” scientific 
discoveries in the primary diseases 
of  poverty (HIV, Malaria, TB) have 
been published; however, no 
vaccine products have been 
approved in these areas since 1921**
* Butler, D et al. (2007)  “Lost 
in Translation”,
Nature. 449, 158
* * FDA and EMEA 
registration data
Background on MEND
Bridging the gap: 
• We are a 501(c)3 not-for-profit devoted to the successful development and 
manufacture of  affordable and effective vaccines and therapies for diseases 
of  poverty with characteristics that allow their widespread use and 
sustainability
• We do this by incubating (and subsequently applying) emerging and 
advanced delivery and manufacturing technologies to drug and vaccine 
candidates for diseases to make them well-suited for the daunting economic 




The global tuberculosis (TB) epidemic:  
• 14.6 million chronic and active cases in 2008 *
• 1.8 million deaths
• 500 000 cases of  MDR TB
• 31% of  cases in Africa
• In terms of  total numbers of  cases in 2008:
 India (2.0 million)
 China (1.3 million) 
 Indonesia (0.53 million) 
 Nigeria (0.46 million)
 South Africa (0.46 million)
* WHO (2009) “Global tuberculosis control”
Focus on TB
Challenges to combating TB in high burden countries:  
• Limited access to drugs and vaccines
• Increasing levels of  drug resistance
• Toxicity of  drugs for MDR TB
• Duration of  treatment, patient default
• Largely ineffective vaccine against pulmonary TB in adults
• Limitations imposed by current diagnostics
• Lack of  incentives for manufacturers
• Cost and risks associated with injections
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BCG – The current TB vaccine
Mycobacterium bovis Bacille Calmette-Guerin (BCG):  
• Developed by Calmette & Guérin (1906-1921)
• The most widely-used childhood vaccine (>100 million doses/year)
• Delivered intradermally
• No new TB vaccine in 88 years
• Requires cold-chain to ensure potency of  vaccine
• Efficacy varies from 0 – 80%
BCG – The current TB vaccine
Variability is due to several reasons: *
• Genetic variability of  vaccinated individuals;
• Unique characteristics of  environmental mycobacteria
• Differences in immunization schedules and doses of  BCG
• BCG strains differing in their genetic, biochemical
• and immunological characteristics;
• Variations in vaccine production – effect of  lyophilization
*  Dietrich, G et al. (2002) Journal of  Biotechnology. 96, 259
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MEND aims to address most of these issues by utilizing an advanced 
and innovative approach to formulating  BCG vaccine
The Mend solution: Targeting BCG to the lung
• Natural route of  infection of  TB
• Hypothesis: immunization via lungs may lead to greater immunity
• Large exposed surface area
• Elimination of  risks associated with needle use
• Mucosal and/or systemic immunity
• Noninvasive – better patient adherence
The Mend solution: Targeting BCG to the lung




• Training of  healthcare workers
• Cold chain
* Giudice, E et al. (2006) Advanced Drug Delivery Reviews. 58, 68
Spray drying: a process to engineer particles for 
inhalation
• David Edwards at Harvard University pioneered the application of  
spray drying in formulating drugs for inhalation
• Large Porous Particles: microparticles are geometrically large (dg = 5 
-10 μm) but with a low mass density ( < 0.4 g/cm3) for optimal 
delivery to the lungs (da = 1–5 μm) 
* 
• Applied to TB drugs:
 Para-aminosalicylic acid (Tsapis N, et al. (2003) Tuberculosis. 83, 379)
 Capreomycin (Garcia-Contreras L, et al. (2007) AAC. 51, 2830)
 PA-824 (Sung JC, et al. (2009) AAC. 53, 1338)
* Edwards DA, et al. (1997) Science. 276, 1868
Spray drying: a process to engineer particles for 
inhalation
• Single-step dehydration technique used in the food, pharmaceutical 
and agricultural industries
• Solvent carrying solubilized substances atomized through a nozzle 
• Rapid drying of  droplets in contact with heated gas
• Separation of  product using cyclone




• Evaporation rates control particle density and thus aerodynamic 
diameter  (Optimum particle size for lung delivery is 1-5 μm)
Spray drying: a process to engineer particles for 
inhalation
• Batch process
• High capital/ops costs
• Requires cold storage
• Poor powder flowability
limits delivery options 
• Continuous process
• Low capital/ops costs
• Retain organism activity by 
controlled drying
• Avoids cold storage
• Flowable powders allows 
diverse delivery options
Lyophilization Spray drying
Spray drying: a process to engineer particles for 
inhalation
Spray drying applied to live whole cells:
• Spray-drying BCG in salt-free suspensions minimizes 
osmotic stresses during drying, thus minimizing loss of  
bacterial viability *
• Microstructural properties adapted to optimize aerosol 
properties
* Wong Y-L, et al. (2007) (2007) PNAS. 104, 2591
Drying Droplet
Preliminary results - Guinea pig study
• Influence of  BCG vaccination by different routes on Tuberculin 
reaction in guinea pigs *
Diameter of Induration (mm)
6 weeks after Vaccination
Treatment Route of 
administration
100 TU 5 TU
BCG Powder Pulmonary 18.60 2.61 11.80 1.92
BCG Solution SC 17.83 1.83 11.33 3.14
Untreated - 0 0
* Garcia-Contreras L, et al. (2008) PNAS. 105, 4656
Preliminary results - Guinea pig study
• Number of  viable bacteria per ml of  tissue homogenate at necropsy 
after bacterial challenge of  animals immunized with BCG *
* Garcia-Contreras L, et al. (2008) PNAS. 105, 4656
Stability studies
• Stability of  spray-dried BCG formulation after storage at 4˚C *
* Wong Y-L, et al. (2007) (2007) PNAS. 104, 2591
Technology transfer to South Africa
• Spray dry facility established in South Africa with funding from Bill 
& Melinda Gates Foundation
• Focus: pharmaceutical development,  production of  material for 
toxicology studies and Phase I human trials
• South Africa has a high burden of  TB sufferers
• Local knowledge and close proximity to where the products will be 
applied
• Availability of  good infrastructure to support operation
• Establishing local expertise in pharmaceutical development of  
inhalable drugs
Technology transfer to South Africa
• Spray drying process and some analytical methods transferred
• Further process and product optimization, validation of  process and  
analytical methods
• Product specifications:  biological and physical properties for alveolar 
delivery:
Physical property Value
BCG content (wt%) 5
Viability (CFU/mg) 1-2x104
Geometric particle size distribution d50 (μm) 3-4
Aerodynamic particle size da (μm) 1.5-2.5
Fine particle fraction < 5.8 μm (%) 50
Density (g/cm3) 0.08-0.1
Moisture content (%) 0.1-0.5
The MEND spray drying facility
• Located at Medical Research Council in Pretoria
• Fully equipped for aseptic production, capsule filling and batch 
release of  whole-cell vaccines according to cGMP requirements
• All the equipment and analytical methods fully validated:
 Andersen Cascade Impactor: aerodynamic particle size distribution
 Sympatec HELOS/RODOS: geometric particle size distribution
 Karl Fischer titrator: moisture content analysis
 Waters HPLC: chemical composition
• Bioanalytical testing:
 Viability determination in terms of  ATP and CFU
 Sterility
 Live/dead assay
The MEND spray drying facility














In 2 animal models
Pre-IND meetings 
with FDA and EMEA
Production of tox 
material and batch 
release
IND meeting with 
FDA and EMEA
Phase I clinical study
Inhaler development
Summary
• MEND has a unique approach to apply Harvard University 
technology to TB vaccine development in SA
• BCG vaccine can be spray dried into viable aerosol with good long 
term stability
• Guinea pig studies show the viable BCG aerosol to be as 
immunogenic as the intradermal control
• Mend has established a GLP laboratory for production of  material 
for toxicology and Phase I human studies
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